Casopitant

From Wikipedia, the free encyclopedia

Casopitant
Systematic (IUPAC) name
(2S,4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
Identifiers
CAS number  ?
ATC code  ?
PubChem 23725089
Chemical data
Formula C30H35F7N4O2 
Mol. mass 616.26 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Casopitant (INN) is an neurokinin 1 receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is developed by GlaxoSmithKline and is likely to be marketed in the US as Rezonic and in the EU as Zunrisa.

[edit] References

  1. ^ Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.